A Food and Drug Administration (FDA) chemist and his son were charged yesterday with Insider Trading. The chemist was granted access to confidential data regarding drug approval reviews. The chemist, it turns out, had access to a database. The chemist then abused these privileges to purchase advance stock of those companies granted approval. According to the report, the chemist was able to profit $3.6 million.
- DARSHNA KAMANI
- InfoSecurity
- Posted On





